Allergy and immunology, Planning

Applied filters

Guidance (33)
- Advanced therapy medicinal products (5)
- Safety in Breastfeeding (23)
- Stability in dosette boxes (12)
- Stability outside the fridge (10)
Medicine (47)
- Alemtuzumab (1)
- Anakinra (1)
- Beclometasone (1)
- Bee venom (1)
- Benralizumab (1)
- Bilastine (1)
- C1-esterase inhibitor (1)
- Cetirizine (1)
- Ciclosporin (1)
- Cladribine (1)
- Conestat alfa (1)
- Desloratadine (1)
- Dimethyl fumarate (1)
- Fingolimod (1)
- Grass pollen (1)
- Human alpha1-proteinase inhibitor (2)
- Icatibant (1)
- Levocetirizine (1)
- Mepolizumab (1)
- Mitoxantrone (1)
- Mizolastine (1)
- Molgramostim (1)
- Naphazoline (1)
- Natalizumab (1)
- Normal immunoglobulin human (1)
- Omalizumab (1)
- Pazopanib (1)
- Peginterferon beta-1a (1)
- Rituximab (1)
- Rupatadine (1)
- Siltuximab (1)
- Tacrolimus (1)
- Teriflunomide (1)
- Trehalose (1)
- Vedolizumab (1)
- Wasp venom (1)
Planning (74)
- Biosimilars (2)
- New Medicines (61)
  - CCG commissioned new medicines (21)
  - NHS England commissioned new medicines (39)
  - Pre-registration new medicines (UK/EU) (5)
- Patent expiries (27)
Specialty (74)
- Allergy and immunology (74)
- Cancers (14)
- Cardiovascular system disorders (1)
- Ear, nose and throat disorders (4)
- Endocrine system disorders (1)
- Eyes and vision (2)
- Gastrointestinal disorders (4)
- Haematological disorders (2)
- Infection and infectious diseases (3)
- Liver disorders (1)
- Musculo-skeletal disorders (3)
- Neurological disorders (2)
- Renal and urologic disorders (2)
- Respiratory disorders (20)
- Skin disorders (8)
- Vaccinating (2)